Baheal Medical (301015.SZ) was recently named on the "2024 China Emerging Pharmaceutical Innovators" list at the 41st National Pharmaceutical Industry Information Conference, hosted by the China National Pharmaceutical Industry Information Center. The conference, themed "Perseverance, Innovation, and Bright Future," focused on the latest industry policy dynamics, explored development trends, and promoted the deep integration of the pharmaceutical industry with the entire innovation ecosystem. During the event, several authoritative lists, including the "2023 Top 100 Chinese Pharmaceutical Companies," were unveiled, with Baheal Medical honored for its initiatives and strategic layout in supporting pharmaceutical innovation.

   The "China Emerging Pharmaceutical Innovators" list, established in 2020, is curated by the China National Pharmaceutical Industry Information Center in collaboration with the Chinese Academy of Medical Sciences and the Shanghai Institute of Pharmaceutical Industry. This expert panel conducts research and analysis based on objective data to identify the rising innovative enterprises within China's pharmaceutical sector. The evaluation criteria for this list are divided into two main categories: products and enterprises. On the product level, the assessment focuses on innovation, investment, technological advancements, and competitive environment. On the enterprise level, the criteria include characteristics, driving forces, strategic planning, and developmental progress.

  Serving as the pharmaceutical industrialization platform that supports upstream innovation, Baheal Medical focuses on the development, manufacturing and commercialization of medical innovations, and effectively optimizing the medical practices through technological innovation. Through its core technical capabilities in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, Baheal Medical has established a sophisticated R&D and production system for both TCM and chemical medicines. The company has successfully launched a variety of innovative products with proprietary intellectual property rights, and consistently drive forward technological development and production for upstream medical innovations. In addition, leveraging its well-established commercialization capabilities and extensive nationwide sales and marketing network, Baheal Medical accelerates the adoption of high-quality medical and health products in clinical practices.This strategic approach has successfully incubated multiple leading brands across various categories.

   In recent years, the parent company, Baheal Pharma Group, has been actively advancing medical innovation by delving deep into the early stages of groundbreaking research in collaboration with national-level research institutions. They seek to cultivate and develop "first-in-class" potential and breakthrough technologies. Aligned with the Group's strategic focus on technological innovation, Baheal Medical has successfully commercialized several cutting-edge products. These include CH Biomedical's fully magnetic levitation artificial heart, Medis's electromagnetic-guided ultrasound puncture devices, and WeHealth's home-use electrocardiographs.

Moreover, Baheal Medical has secured commercialization rights for innovative products such as RADIO Pharma's first-in-class nuclear medicine tumor imaging diagnostic agent 99mTc-3PRGD2 and SPECT imaging devices, as well as RabPharma's pioneering peptide-drug conjugate (PDC) therapeutics. This strategic approach ensures that Baheal Pharma remains at the forefront of medical innovation and continues to bring advanced medical solutions to market.

Looking ahead, as the Group's early-stage innovations come to fruition, BAHEAL will leverage its industrial capabilities to drive the production and commercialization of cutting-edge pharmaceuticals and medical devices. This will accelerate the introduction of breakthrough medical products into clinical settings. BAHEAL remains committed to contributing to the flourishing development of medical innovation in China, driving progress in medical science and technology.